Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $9.82 on NeoGenomics, Inc. (NASDAQ:NEO) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $0.12 for the next fiscal and $N/A for underway quarter. Valuation Estimates Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of NeoGenomics, Inc. (NASDAQ:NEO) stands at N/A. Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For NeoGenomics, Inc., the PEG ratio for coming 3-5 years is 3.31. Technical Analysis The technical analysis highlights that NeoGenomics, Inc. current price is trading $-0.74 points away -8.70% from $8.51, which stands as the 50-day moving average of the firm. The stock’s 200-day MA is $7.35 and, for now, the stock price is trading $0.42 or +5.66% away from that point. The 52-week high of NeoGenomics, Inc. (NASDAQ:NEO) was $9.17 while lowest point recorded in 52-week was $5.05. It implies if stock price makes a movement of over $-1.40, it will record a new 52-week high. In the case of $+53.86% points drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know